Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugenia Shmidt

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Cell Reports|October 5, 2021
High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccinesKathryn A Pape, Thamotharampillai Dileepan, Amanda J Kabage, et al.
The American Journal of Gastroenterology|June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY ConsortiumParambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.
JCI Insight|June 22, 2022
Boosting corrects a memory B cell defect in SARS-CoV-2 mRNA-vaccinated patients with inflammatory bowel diseaseKathryn A Pape, Thamotharampillai Dileepan, William E Matchett, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cell Reports|October 5, 2021
High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccinesKathryn A Pape, Thamotharampillai Dileepan, Amanda J Kabage, et al.
The American Journal of Gastroenterology|June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY ConsortiumParambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.
JCI Insight|June 22, 2022
Boosting corrects a memory B cell defect in SARS-CoV-2 mRNA-vaccinated patients with inflammatory bowel diseaseKathryn A Pape, Thamotharampillai Dileepan, William E Matchett, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Pageof 5